Therapeutic Response

FGFR2 rearrangements status confers therapeutic sensitivity to Elacestrant in patients with Cholangiocarcinoma.

Statements

Source and description
Pemazyre (pemigatinib) [product information]. EMA. The European Medicines Agency (EMA) has conditionally authorized pemigatinib for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.